Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
From Ocular Therapeutix, Inc.
Via Business Wire
Tickers OCUL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.